FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378194803> ?p ?o ?g. }

• W4378194803 endingPage "e15925" @default.
• W4378194803 startingPage "e15925" @default.
• W4378194803 abstract "BackgroundImmune checkpoint inhibitor (ICI) treatment has enhanced survival outcomes in clear cell renal cell carcinoma (ccRCC) patients. Nevertheless, the effectiveness of immunotherapy in ccRCC patients is restricted and we intended to develop and characterize an immune response prediction signature (IRPS) to forecast the efficacy of immunotherapy.MethodsRNA-seq expression profile and clinicopathologic characteristics of 539 kidney cancer and 72 patients with normal specimens, were downloaded from the Cancer Genome Atlas (TCGA) database, while the Gene Expression Omnibus (GEO) database was used as the validation set, which included 24 ccRCC samples. Utilization of the TCGA data and immune genes databases (ImmPort and the InnateDB), we explored through Weighted Gene Co-expression Network Analysis (WGCNA), along with Least Absolute Shrinkage and Selection Operator method (LASSO), and constructed an IRPS for kidney cancer patients. GSEA and CIBERSORT were performed to declare the molecular and immunologic mechanism underlying the predictive value of IRPS. The Human Protein Atlas (HPA) was deployed to verify the protein expressions of IRPS genes. Tumor immune dysfunction and exclusion (TIDE) score and immunophenoscore (IPS) were computed to determine the risk of immune escape and value the discrimination of IRPS. A ccRCC cohort with anti-PD-1 therapy was obtained as an external validation data set to verify the predictive value of IRPS.ResultsWe constructed a 10 gene signature related to the prognosis and immune response of ccRCC patients. Considering the IRPS risk score, patients were split into high and low risk groups. Patients with high risk in the TCGA cohort tended towards advanced tumor stage and grade with poor prognosis (p < 0.001), which was validated in GEO database (p = 0.004). High-risk group tumors were related with lower PD-L1 expression, higher TMB, higher MSIsensor score, lower IPS, higher TIDE score, and enriched Treg cells, which might be the potential mechanism of immune dysfunction and exclusion. Patients in the IRPS low risk group had better PFS (HR:0.73; 95% CI: 0.54–1.0; P = 0.047).ConclusionA novel biomarker of IRPS was constructed to predict the benefit of immunotherapy, which might lead to more individualized prognoses and tailored therapy for kidney cancer patients." @default.
• W4378194803 created "2023-05-26" @default.
• W4378194803 creator A5002240897 @default.
• W4378194803 creator A5050378807 @default.
• W4378194803 creator A5060165452 @default.
• W4378194803 creator A5067799719 @default.
• W4378194803 creator A5085243153 @default.
• W4378194803 creator A5002765618 @default.
• W4378194803 date "2023-06-01" @default.
• W4378194803 modified "2023-10-09" @default.
• W4378194803 title "Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients" @default.
• W4378194803 cites W1966327575 @default.
• W4378194803 cites W1982488143 @default.
• W4378194803 cites W1999793633 @default.
• W4378194803 cites W2035473115 @default.
• W4378194803 cites W2060469376 @default.
• W4378194803 cites W2105896173 @default.
• W4378194803 cites W2117564738 @default.
• W4378194803 cites W2152061559 @default.
• W4378194803 cites W2203305073 @default.
• W4378194803 cites W2222086386 @default.
• W4378194803 cites W2560367415 @default.
• W4378194803 cites W2572174216 @default.
• W4378194803 cites W2611919322 @default.
• W4378194803 cites W2622499649 @default.
• W4378194803 cites W2782676239 @default.
• W4378194803 cites W2797855256 @default.
• W4378194803 cites W2886498337 @default.
• W4378194803 cites W2888408613 @default.
• W4378194803 cites W2904444972 @default.
• W4378194803 cites W2909679049 @default.
• W4378194803 cites W2920863623 @default.
• W4378194803 cites W2947199108 @default.
• W4378194803 cites W2949273159 @default.
• W4378194803 cites W2951323337 @default.
• W4378194803 cites W2974687396 @default.
• W4378194803 cites W2981221200 @default.
• W4378194803 cites W2990642475 @default.
• W4378194803 cites W2996285493 @default.
• W4378194803 cites W3002312154 @default.
• W4378194803 cites W3005088442 @default.
• W4378194803 cites W3005186000 @default.
• W4378194803 cites W3006825051 @default.
• W4378194803 cites W3015126270 @default.
• W4378194803 cites W3025451213 @default.
• W4378194803 cites W3029490475 @default.
• W4378194803 cites W3083986479 @default.
• W4378194803 cites W3093923068 @default.
• W4378194803 cites W3097956869 @default.
• W4378194803 cites W3111942073 @default.
• W4378194803 cites W3114743310 @default.
• W4378194803 cites W3116888808 @default.
• W4378194803 cites W3118551423 @default.
• W4378194803 cites W3125477438 @default.
• W4378194803 cites W3126738486 @default.
• W4378194803 cites W3132812950 @default.
• W4378194803 cites W3136653115 @default.
• W4378194803 cites W3138455591 @default.
• W4378194803 cites W3172911572 @default.
• W4378194803 cites W3177404835 @default.
• W4378194803 cites W3184068580 @default.
• W4378194803 cites W3201074739 @default.
• W4378194803 cites W3202400684 @default.
• W4378194803 cites W3205716412 @default.
• W4378194803 cites W3216005024 @default.
• W4378194803 cites W4205743659 @default.
• W4378194803 cites W4206841660 @default.
• W4378194803 cites W4224210658 @default.
• W4378194803 cites W4285589935 @default.
• W4378194803 doi "https://doi.org/10.1016/j.heliyon.2023.e15925" @default.
• W4378194803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37484396" @default.
• W4378194803 hasPublicationYear "2023" @default.
• W4378194803 type Work @default.
• W4378194803 citedByCount "0" @default.
• W4378194803 crossrefType "journal-article" @default.
• W4378194803 hasAuthorship W4378194803A5002240897 @default.
• W4378194803 hasAuthorship W4378194803A5002765618 @default.
• W4378194803 hasAuthorship W4378194803A5050378807 @default.
• W4378194803 hasAuthorship W4378194803A5060165452 @default.
• W4378194803 hasAuthorship W4378194803A5067799719 @default.
• W4378194803 hasAuthorship W4378194803A5085243153 @default.
• W4378194803 hasBestOaLocation W43781948031 @default.
• W4378194803 hasConcept C104317684 @default.
• W4378194803 hasConcept C10515644 @default.
• W4378194803 hasConcept C121608353 @default.
• W4378194803 hasConcept C126322002 @default.
• W4378194803 hasConcept C143998085 @default.
• W4378194803 hasConcept C150194340 @default.
• W4378194803 hasConcept C203014093 @default.
• W4378194803 hasConcept C2777472916 @default.
• W4378194803 hasConcept C2777701055 @default.
• W4378194803 hasConcept C2779733811 @default.
• W4378194803 hasConcept C2780851360 @default.
• W4378194803 hasConcept C2781068499 @default.
• W4378194803 hasConcept C2781278892 @default.
• W4378194803 hasConcept C55493867 @default.
• W4378194803 hasConcept C71924100 @default.
• W4378194803 hasConcept C72563966 @default.

• next